@Article{Żychowska2016,
journal="Dermatology Review/Przegląd Dermatologiczny",
issn="0033-2526",
volume="103",
number="5",
year="2016",
title="Severe cicatricial alopecia as a rare cutaneous side effect due to erlotinib – case report",
abstract=" Introduction . Epidermal growth factor receptor inhibitors (EGFRI) are commonly used in the treatment of solid tumors. Cutaneous side effects occur in 80% of patients and are the most frequent adverse events. However, cicatricial alopecia is a rarely described side effect of EGFRI.   Objective . To present cutaneous toxicities in a patient treated with erlotinib and underscore cicatricial alopecia, rarely described in the literature.   Case report.   We present a 63-year-old woman diagnosed with non-small cell lung cancer and treated with erlotinib, who developed extensive papulo-pustular eruption with severe involvement of the scalp and cicatricial alopecia. Other adverse events included trichomegaly, paronychia, granuloma pyogenicum-like lesions, dryness of the skin and pruritus.   Conclusions . Cicatricial alopecia in the presented patient may be a result of delayed introduction of dermatological treatment. Therefore, all dermatologists should be aware of treatment modalities of EGFRI-induced toxicities.",
author="Żychowska, Magdalena
and Batycka-Baran, Aleksandra
and Baran, Wojciech
and Maj, Joanna",
pages="371--375",
doi="10.5114/dr.2016.62888",
url="http://dx.doi.org/10.5114/dr.2016.62888"
}